AVITA Medical Names Robin VanDenburgh as SVP of U.S. Commercial Sales
AVITA Medical (NASDAQ: RCEL, ASX: AVH) has appointed Robin VanDenburgh as Senior Vice President of U.S. Commercial Sales, effective August 6, 2024. VanDenburgh, previously Vice President of Key Accounts at Smith & Nephew, brings over 25 years of experience in healthcare sales leadership. CEO Jim Corbett expressed confidence in VanDenburgh's ability to expand market presence and drive sales growth for AVITA's wound care solutions, particularly the RECELL GO product.
VanDenburgh's extensive background includes 12 years at Smith & Nephew in senior sales management roles within their advanced wound division. She has also held key positions at Aureon Biosciences, St. Jude Medical, and Ethicon Endo-Surgery. Her expertise in building high-performing sales teams and driving new product adoption is expected to accelerate AVITA Medical's commercial success in the U.S. market.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) ha nominato Robin VanDenburgh come Vicepresidente Senior delle Vendite Commerciali negli Stati Uniti, con effetto dal 6 agosto 2024. VanDenburgh, precedentemente Vicepresidente dei Clienti Chiave presso Smith & Nephew, porta con sé oltre 25 anni di esperienza nella leadership delle vendite nel settore sanitario. Il CEO Jim Corbett ha espresso fiducia nella capacità di VanDenburgh di espandere la presenza sul mercato e incrementare la crescita delle vendite per le soluzioni di cura delle ferite di AVITA, in particolare per il prodotto RECELL GO.
Il vasto background di VanDenburgh include 12 anni presso Smith & Nephew in ruoli di gestione senior delle vendite all'interno della loro divisione avanzata per le ferite. Ha ricoperto anche posizioni chiave presso Aureon Biosciences, St. Jude Medical ed Ethicon Endo-Surgery. La sua esperienza nel costruire team di vendita ad alte prestazioni e nel favorire l'adozione di nuovi prodotti è prevista per accelerare il successo commerciale di AVITA Medical nel mercato statunitense.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) ha nombrado a Robin VanDenburgh como Vicepresidenta Senior de Ventas Comerciales en los EE. UU., con efecto desde el 6 de agosto de 2024. VanDenburgh, anteriormente Vicepresidenta de Cuentas Clave en Smith & Nephew, aporta más de 25 años de experiencia en liderazgo de ventas en el sector de la salud. El CEO Jim Corbett expresó confianza en la capacidad de VanDenburgh para expandir la presencia en el mercado y impulsar el crecimiento de ventas para las soluciones de cuidado de heridas de AVITA, especialmente para el producto RECELL GO.
El amplio historial de VanDenburgh incluye 12 años en Smith & Nephew en roles de alta dirección de ventas dentro de su división avanzada de heridas. También ha ocupado posiciones clave en Aureon Biosciences, St. Jude Medical y Ethicon Endo-Surgery. Se espera que su experiencia en crear equipos de ventas de alto rendimiento y en promover la adopción de nuevos productos acelere el éxito comercial de AVITA Medical en el mercado estadounidense.
AVITA Medical (NASDAQ: RCEL, ASX: AVH)는 Robin VanDenburgh를 미국 상업 영업의 수석 부사장으로 임명하며 2024년 8월 6일부로 발효된다고 발표했습니다. VanDenburgh는 이전에 Smith & Nephew에서 주요 고객 부사장을 역임하며, 의료 판매 리더십 분야에서 25년 이상의 경험을 가지고 있습니다. CEO Jim Corbett는 VanDenburgh가 AVITA의 상처 치료 솔루션, 특히 RECELL GO 제품의 시장 존재를 확장하고 판매 성장을 촉진할 수 있는 능력에 대해 신뢰를 보였습니다.
VanDenburgh는 Smith & Nephew에서 고급 상처 부문에서 12년 동안 고위 영업 관리 역할을 수행한 방대한 경력을 가지고 있습니다. 또한 Aureon Biosciences, St. Jude Medical, Ethicon Endo-Surgery에서 주요 직책을 맡았습니다. 고성능 판매 팀 구축 및 신제품 채택 촉진에 대한 그녀의 전문성은 AVITA Medical의 미국 시장에서의 상업적 성공을 가속화할 것으로 기대됩니다.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) a nommé Robin VanDenburgh au poste de Vice-Présidente Senior des Ventes Commerciales aux États-Unis, avec effet le 6 août 2024. VanDenburgh, précédemment Vice-Présidente des Comptes Clés chez Smith & Nephew, apporte plus de 25 ans d'expérience dans le leadership des ventes en santé. Le PDG Jim Corbett a exprimé sa confiance dans la capacité de VanDenburgh à étendre la présence sur le marché et à stimuler la croissance des ventes des solutions de soins des plaies d'AVITA, en particulier le produit RECELL GO.
Le vaste parcours de VanDenburgh comprend 12 ans chez Smith & Nephew dans des rôles de gestion des ventes senior au sein de leur division avancée des plaies. Elle a également occupé des postes clés chez Aureon Biosciences, St. Jude Medical et Ethicon Endo-Surgery. Son expertise dans la construction d'équipes de vente performantes et la promotion de l'adoption de nouveaux produits devrait accélérer le succès commercial d'AVITA Medical sur le marché américain.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) hat Robin VanDenburgh zum Senior Vice President für den kommerziellen Verkauf in den USA ernannt, mit Wirkung zum 6. August 2024. VanDenburgh, zuvor Vice President für Hauptkunden bei Smith & Nephew, bringt über 25 Jahre Erfahrung im Bereich Verkaufsführung im Gesundheitswesen mit. CEO Jim Corbett äußerte Vertrauen in VanDenburghs Fähigkeit, die Marktpräsenz auszubauen und das Vertriebwachstum für AVITAs Wundversorgungslösungen, insbesondere das Produkt RECELL GO, voranzutreiben.
VanDenburghs umfangreicher Hintergrund umfasst 12 Jahre bei Smith & Nephew in leitenden Vertriebsmanagement-Rollen innerhalb ihrer fortgeschrittenen Wundabteilung. Sie hatte auch Schlüsselpositionen bei Aureon Biosciences, St. Jude Medical und Ethicon Endo-Surgery inne. Ihre Expertise im Aufbau leistungsstarker Vertriebsteams und im Fördern der Akzeptanz neuer Produkte wird voraussichtlich den kommerziellen Erfolg von AVITA Medical auf dem US-Markt beschleunigen.
- Appointment of experienced industry leader Robin VanDenburgh as SVP of U.S. Commercial Sales
- VanDenburgh brings over 25 years of experience in healthcare sales leadership
- Potential for expanded market presence and sales growth in the U.S.
- Strategic hire to drive adoption of RECELL GO and other wound care solutions
- None.
VALENCIA, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, is pleased to announce that industry leader Robin VanDenburgh has joined as Senior Vice President of U.S. Commercial Sales, effective August 6, 2024. VanDenburgh, who most recently served as Vice President of Key Accounts at Smith & Nephew (NYSE: SNN), will spearhead AVITA Medical’s efforts to expand its market presence and drive sales growth in the U.S.
“Robin brings a wealth of experience in leading and developing high-performing sales teams,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “Her proven ability to drive new product adoption and growth across multiple specialties makes her the ideal leader to expand the treatment capabilities of RECELL GO and advance our innovative portfolio of wound care solutions. We are confident that her strategic vision and industry expertise will be instrumental in driving our U.S. commercial success and accelerating growth.”
VanDenburgh is an accomplished executive with more than 25 years of experience building sales teams and driving revenue growth in the healthcare industry. During her 12-year tenure at Smith & Nephew, she held senior-level sales management positions of increasing responsibility with cross-functional responsibility within their advanced wound division, which included medical devices, biologics, and dressings. Prior to that, she held a sales management position at Aureon Biosciences, where she managed and developed a new sales team,
About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, in the United States.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE-mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements concerning the potential for future growth of our business and our ability to achieve financial goals. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/657160c0-7585-4093-8b52-fb05f8da004f
FAQ
Who is the new Senior Vice President of U.S. Commercial Sales at AVITA Medical (RCEL)?
What is Robin VanDenburgh's previous experience before joining AVITA Medical (RCEL)?
What are the main objectives for Robin VanDenburgh in her new role at AVITA Medical (RCEL)?
When does Robin VanDenburgh start her new position at AVITA Medical (RCEL)?
